biopharmaceutical

Biologics X 3DCC Conference 2026: Merging Innovation, Drug Development, and Translation for the Next Era of Biopharma

 Registrations OPEN India's first of-its-kind, 6th Annual Summit on Biopharmaceutical Product Development in conjunction with the 3rd edition of the International Conference…

2 weeks ago

Psyence BioMed Announces Approval for Use of PsyLabs Psilocybin Product in Phase IIb Clinical Trial

NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical…

2 weeks ago

TOMI Environmental Solutions Secures a Purchase Order of Approximately $500,000 for the Integration of SteraMist iHP Technology within a Global Biopharmaceutical Leader

December 18, 2025 09:00 ET  | Source: TOMI Environmental Solutions, Inc. FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- TOMI…

3 weeks ago

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics,…

3 weeks ago

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome

– Company to host live webcast and conference call Monday, December 15, 2025 at 8:00 am ET – December 14,…

3 weeks ago

Latest Data of InnoCares Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)

December 08, 2025 21:04 ET  | Source: InnoCare Pharma BEIJING, Dec. 08, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969;…

4 weeks ago

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure frequency (CMSF)…

4 weeks ago

Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients

Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment…

4 weeks ago

Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinsons Disease

December 05, 2025 21:00 ET  | Source: Cerevance, Inc. Phase 2 results selected as one of only 10 featured presentations…

4 weeks ago

Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program

November 28, 2025 20:13 ET  | Source: Rakovina Therapeutics Inc VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina…

1 month ago